Inogen shares nosedive after poor fourth-quarter earnings
Shares of Goleta-based Inogen have nosedived 32% in the days since the company’s fourth quarter and full-year earnings results. Inogen, a maker of portable oxygen containers, announced on Feb. 23 that it suffered a net loss of $56.6 million for the quarter ended Dec. 31, up substantially from a net loss of $22.8 million in Read More →
Olaplex’s struggles continue in fourth quarter
Sales and earnings fell yet again for Olaplex Holdings, a Montecito-based hair products seller, in the fourth quarter of 2022 leading to shares dropping nearly 10% during the trading day Feb. 28. Olaplex presented a net income of $33.6 million or 5 cents per diluted share for the quarter that ended Dec. 31, down from Read More →
Procore aims for lower net loss, continued high growth in 2023
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
LTC Properties posts fourth-quarter earnings
LTC Properties, the real estate investment trust based in Westlake Village that chiefly invests in senior living and health care properties, announced its fourth-quarter results for the period ending December 31. Net income increased by 39.9%, from $12.7 million to $17.8 million or in terms of diluted earnings per common share, from 32 cents to Read More →
Amgen’s $150 million investment aims to scale, diversify middle-market business
By Mark Alfred Special to the Business Times Thousand Oaks-based Amgen, one of the largest biotechnology companies in the world, invested $150 million into Project Black: an Ariel Investments fund intended to transform middle-market companies into certified minority-owned business enterprises. The fund, managed by Ariel’s private equity subsidiary Ariel Alternatives, is based in Chicago. It Read More →
The Trade Desk outperforms competition to close out fiscal year
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Atara’s cuts down net loss in 2022
Atara Biotherapeutics recorded a lower net loss in the fourth quarter and the entirety of fiscal year 2022, but missed expectations still led to an 8% decline in after-hours trading. Atara, a South San Francisco-based immunotherapy company with its major operations in Thousand Oaks, reported a net loss of $228.3 million, or 2.24 cents per Read More →
